

Novavax COVID Vaccines Should Carry Heart Inflammation Warning, EU Says

By [Megan Redshaw](#)

Global Research, August 04, 2022

[Children's Health Defense](#) 3 August 2022

Region: [Europe](#)

Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

To receive Global Research’s Daily Newsletter (selected articles), [click here](#).

Visit and follow us on [Instagram](#), [Twitter](#) and [Facebook](#). Feel free to repost and share widely Global Research articles.

The European Medicines Agency today recommended adding a warning for two types of heart inflammation to Novavax’s COVID-19 vaccine, marketed under the brand names Nuvaxovid and Covovax, based on a small number of cases reported in those who received the vaccine.

According to a [statement](#), the EMA’s [Pharmacovigilance Risk Assessment Committee](#) — responsible for assessing and monitoring the safety of human medicines — concluded that “myocarditis and pericarditis can occur following vaccination with Nuvaxovid.”

“The Committee is therefore recommending listing myocarditis and pericarditis as new side effects in the product information for Nuvaxovid, together with a warning to raise awareness among healthcare professionals and people receiving this vaccine,” the statement said.

The Pharmacovigilance Risk Assessment Committee also requested the “marketing authorization holder of Nuvaxovid [provides additional data](#) on risk of side effects occurring.”

According to [Reuters](#), the U.S. Food and Drug Administration (FDA) flagged a risk of heart inflammation from the Novavax vaccine in early June.

However, the agency on July 13 [granted Novavax’s request](#) for Emergency Use Authorization of the vaccine for adults 18 and over in the U.S.

Novavax hoped people who opted not to take Pfizer and Moderna mRNA vaccines — both of which are associated with a [risk of heart inflammation](#) — would favor its shot because it “relies on technology used for decades,” [Reuters reported](#).

The FDA’s “Fact Sheet for Healthcare Providers Administering Vaccine” now [includes a warning](#) that “clinical trial data provide evidence for increased risks of myocarditis

(inflammation of the heart muscle) and pericarditis (inflammation of tissue surrounding the heart) following administration of Novavax COVID-19 Vaccine, Adjuvanted.”

The FDA’s “Fact Sheet for Recipients and Caregivers” states that for most people who have had myocarditis or pericarditis after receiving the vaccine, symptoms began within 10 days following vaccination and that vaccine recipients should seek medical attention right away if they experience chest pain, shortness of breath, feelings of having a fast-beating, fluttering or pounding heart.

[Myocarditis](#) is inflammation of the heart muscle that can lead to cardiac arrhythmia and death. According to the [National Organization for Rare Disorders](#), myocarditis can result from infections, but “more commonly the myocarditis is a result of the body’s immune reaction to the initial heart damage.”

[Pericarditis](#) is inflammation of the tissue surrounding the heart that can cause sharp chest pain and other symptoms.

Unlike the Pfizer and Moderna vaccines that [use mRNA technology](#), and the Johnson & Johnson (J&J) vaccine that uses adenovirus vector technology, the Novavax vaccine uses a more traditional vaccine technology.

As [The Defender reported](#) in June, that may be one reason the committee recommended the vaccine — in the hope that “unvaccinated holdouts,” suspicious of the newer technologies or allergic to components of the mRNA vaccines, will be more likely to get the Novavax shot.

Despite a unanimous vote by the FDA’s vaccine advisory panel, members raised several concerns about the Novavax vaccine, including heart-related adverse events observed during the clinical trials.

FDA [documents](#) show multiple instances of myocarditis and pericarditis reported after the administration of the Novavax vaccine:

“Multiple events of myocarditis/pericarditis were reported in temporal relationship to NVX-CoV2373 [the Novavax vaccine used during the trials] administration, similar to myocarditis following mRNA COVID-19 vaccines and raising concern for a causal relationship to NVX-CoV2373.

“Events of lymphadenopathy were infrequent but reported by a higher proportion of participants in the NVX arm, with the highest rate observed after Dose 2 (0.2%).

“Review of the data also identified small imbalances in certain thromboembolic events, including cardiac and neurovascular events, hypersensitivity events, cholecystitis, uveitis, cardiac failure, and cardiomyopathy.

“Data from passive surveillance during post-authorization use in other countries also indicate a higher-than-expected rate of myocarditis and pericarditis (mainly pericarditis) associated with the vaccine.”

In a safety database encompassing data from 40,000 Novavax vaccine recipients, four young men, ages 16 through 28, [reported](#) myocarditis or pericarditis within 20 days of injection, though one of the four had a viral illness that may have caused the symptoms.

One trial participant [reported](#) myocarditis after being injected with a placebo.

According to the [FDA](#), there were 26,000 people in the Novavax clinical trial. Yet, only 21,000 of the 26,000 people who received the vaccine during the trial were “followed for at least 2 months.”

It is unknown if any participants developed heart inflammation after the two-month follow-up period, why the other 5,000 clinical trial participants were not followed or whether those individuals experienced heart inflammation.

In briefing documents [released](#) June 3, the FDA [wrote](#):

“These events raise the concern for a causal association with this vaccine, similar to the association documented with mRNA COVID-19 vaccines.”

The FDA [asked Novavax](#) to “flag” myocarditis and pericarditis as an “important identified risk” in its materials accompanying the vaccine. However, Novavax has not yet agreed to do so.

“Based on our interpretation of all the clinical data supporting NVX-CoV2373 ... we believe there is insufficient evidence to establish a causal relationship,” the company said in a statement.

Novavax claimed that “natural background events” of myocarditis can be expected in any large database and the “totality of the clinical evidence” is “not [enough to establish](#) an overall causal relationship with the vaccine.”

Novavax on Monday [asked](#) the World Health Organization to expand emergency use listing of its vaccine for adolescents ages 12-17. [Japan](#), [Australia](#) and the [EU](#) previously authorized the vaccine for that age group.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

Megan Redshaw is a staff attorney for Children's Health Defense and a reporter for The Defender.

Featured image is from CHD

The original source of this article is [Children's Health Defense](#)
Copyright © [Megan Redshaw](#), [Children's Health Defense](#), 2022

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Megan Redshaw](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca